Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Interest & Investment Income (2016 - 2026)

Ironwood Pharmaceuticals' Interest & Investment Income history spans 16 years, with the latest figure at $1.5 million for Q4 2025.

  • On a quarterly basis, Interest & Investment Income rose 87.53% to $1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.1 million, a 8.77% decrease, with the full-year FY2025 number at $4.1 million, down 8.77% from a year prior.
  • Interest & Investment Income hit $1.5 million in Q4 2025 for Ironwood Pharmaceuticals, up from $930000.0 in the prior quarter.
  • Over the last five years, Interest & Investment Income for IRWD hit a ceiling of $8.8 million in Q2 2023 and a floor of $172000.0 in Q2 2021.
  • Historically, Interest & Investment Income has averaged $1.9 million across 5 years, with a median of $1.1 million in 2022.
  • Biggest five-year swings in Interest & Investment Income: soared 3061.74% in 2023 and later plummeted 84.37% in 2024.
  • Tracing IRWD's Interest & Investment Income over 5 years: stood at $180000.0 in 2021, then surged by 2925.56% to $5.4 million in 2022, then plummeted by 78.08% to $1.2 million in 2023, then tumbled by 34.84% to $778000.0 in 2024, then skyrocketed by 87.53% to $1.5 million in 2025.
  • Business Quant data shows Interest & Investment Income for IRWD at $1.5 million in Q4 2025, $930000.0 in Q3 2025, and $818000.0 in Q2 2025.